nach oben

European Child & Adolescent Psychiatry

Erschienen in:

01.06.2007 | ORIGINAL CONTRIBUTION

The EU-regulation on medicinal products for paediatric use

Impacts on child and adolescent psychiatry and clinical research with minors

verfasst von: Michael Kölch, Kathlen Schnoor, Jörg M. Fegert

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

At present the EU-regulation on medicinal products for paediatric use is in the final legislation phase. The Regulation will bring essential changes to the policy of research with minors, to funding and to regulations of drug development in Europe.

Method

The article analyses contents of the regulation and possible effects on research with and treatment of mentally ill minors.

Results

The regulation seems to be a chance to improve pharmacological treatment for children and bring similar research conditions to Europe as they already exist in the US. Some terms of the regulation must be considered as critical due to vague definitions and ambiguously defined policies in some articles. The designated expert committee will be a powerful institution, but it remains to be seen whether this committee will act in the intended way. It is an existing and real danger that European child and adolescent psychiatry will be neglected by the new regulation, if there is no participation of scientists of this discipline in committees. The regulation makes it necessary for child and adolescent psychiatry to strengthen research in clinical trials and developmental psychopharmacology to get benefits from new legislation and improve health care for mentally ill minors.

Minors are defined as people younger than 18 years. This definition of minors is according to the definition of the EU-regulation, whose defines paediatric population as the population between 0 and 18 years.

Baber NS (2005) Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children? Brit J Clin Pharmacol 59:6660–6662

Bodenheimer T (2000) Uneasy alliance–clinical investigators and the pharmaceutical industry. N Engl J Med 342(20):1539–1544PubMedCrossRef

Bücheler R, Schwab M, Mörike K, Kalchthaler B, Mohr H, Schröder H, Schwoerer P, Gleiter CH (2002) Off-label prescribing to outpatient children. Brit Med J 324:1311–1312PubMedCrossRef

Commission of the European Communities (2004) Proposal for a Regulation of the European Parliament and the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 (presented by the Commission) {SEC(2004) 1144} COM(2004) 599 final 2004/0217 (COD), Brussels, 29.9.2004

Commission of the European Communities (2005) Amended proposal for a Regulation of the European Parliament and the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 (presented by the Commission pursuant to Article 250 (2) of the EC Treaty), COM(2005) 577 final, 2004/0217 (COD), Brussels, 10.11.2005

Commission of the European Communities (2006) Communication from the Commission to the European Parliament pursuant to the second subparagraph of Article 251 (2) of the EC Treaty concerning the common position of the Council with a view to the adoption of a regulation on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, COM(2006) 118 final, 2004/0217(COD), Brussels, 13.3.2006

Conroy S, Choonara I, et al. (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. Brit Med J 320(7227):79–82PubMedCrossRef

EMEA (2006) Paediatric Working Party (PEG) Work programme for 2006, EMEA/CHMP/406990/2005, http://www.emea.eu.int/pdfs/human/peg/40699005en.pdf (access verified 22 June 2006)

Entorf H, Fegert JM, et al. (2004) Children in need of medical innovation, ZEW Zentrum für Europäische Wirtschaftsforschung GmbH:28

10.

European Commission (2001) Directive 2001/20/EC Official Journal of the European Communities L 121/34

11.

Fegert JM, Kölch M, et al. (2003) Sichere und wirksame Arzneimittel auch für Kinder. Z Rechtspol 36(12):446–450

12.

Food and Drug Administration (2003): Approved moieties to which FDA has granted pediatric exclusivity for pediatric studies under section 505A of the Federal Food, Drug and Cosmetic Act. Available at: http://www.fda.gov/cder/pediatric/exgrant.htm, accessed July 19, 2006

13.

Grieve J, Tordoff J, Reith D, Norris P (2005) Effect of the pediatric exclusivity provision on children’s access to medicines. Brit J Clin Pharmacol 59:(6) 730–735CrossRef

14.

Ian CK, Wong FMCB, Paramala JS, Macey LM (2004) Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Safety 27(13):991–1000CrossRef

15.

Insel T, Nakamura (2006) The value and limitations of large practical clinical trials in informing practice: The NIMH Perspective; Program from 46th Annual Meeting NCDEU, Boca

16.

Klein DF (2006) The flawed basis for FDA post-marketing safety decisions: the example of antidepressants and children. Neuropsychopharmacology 31:689–699PubMedCrossRef

17.

Knöppel C, Klinger O, Soergel M, Seyberth HW, Leonhardt A (2000) Anwendung von Medikamenten außerhalb der Zulassung oder ohne Zulassung bei Kindern. Monatschr Kinderheilkd 148:904–908CrossRef

18.

Kölch M, Lippert HD, Fegert JM (2006). Die Auswirkungen der 12. und der 14. Novelle zum AMG auf die Forschung mit Arzneimitteln für Kinder. Eine Übersicht zu den Neuregelungen, Zeitschrift für Kinder- und Jugendpsychiatrie. Z Kinder Jugendpsychiatr 34(2):117–126CrossRef

19.

Lieberman JA, Stroup TS, et al. (2005) Effectiveness of antipsychotic drugs in patients with schizophrenia (CATIE-study). N Engl J Med 353(12):1209–1223PubMedCrossRef

20.

March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. : JAMA. 2004 Aug 18;292(7):807–820

21.

MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactive disorder. Arch Gen Psychiatry 56, 1073–1086

22.

Rose K (2005) Better medicines for children- where are we and where do we want to be? Brit J Clin Pharmacol 06/2005 59(6):657CrossRef

23.

Schubert Silvia, Lippert Hans-Dieter, Fegert Jörg M, Kölch Michael (2006) Industrieunabhängige Forschung an Kindern und die 12. Novelle des Arzneimittelgesetzes Eine Studie zum Vergleich klinischer Prüfungen vor und nach der 12. Novelle des Arzneimittelgesetzes ( = A comparison of industry sponsored and investigator initiated trials in children before and after the 12th amendment of German drug law) Monatschrift Kinderheilkunde (in press)

24.

Seyberth HW (2006) Zukünftige Anforderungen aus pädiatrischer Sicht ( = future requirements on the Regulation – the point of view of paediatrics lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz

25.

Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:S693–S695

26.

Sudhop T (2006) Voraussetzungen und Durchführung pädiatrischer klinischer Prüfungen aus Sicht einer Bundesoberbehörde ( = Prerequisities and conduct of clinical trials - the point of view of a regulation authority), lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz

27.

Tan J, Fegert JM (2004) Capacity and competence in child and adolescent psychiatry. Health Care Anal 12(4):285–294PubMedCrossRef

28.

Vitiello B, Heiligenstein JH, et al. (2004) The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biol Psychiatry 56:3–9PubMedCrossRef

29.

Werner E. (2006) Europäische Kinderarzneimittelverordnung ( = European Regulation on medicinal products for paediatric use), lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz

30.

Zito JM, Derivan AT, Greenhill L (2004) Making research data available: an ethical imperative demonstrated by the SSRI debacle. J Am Acad Child Adoles Psychiatry 43(5):512–514CrossRef

Titel: The EU-regulation on medicinal products for paediatric use
Impacts on child and adolescent psychiatry and clinical research with minors
verfasst von: Michael Kölch
Kathlen Schnoor
Jörg M. Fegert
Publikationsdatum: 01.06.2007
Verlag: D. Steinkopff-Verlag
Erschienen in: European Child & Adolescent Psychiatry / Ausgabe 4/2007
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-006-0594-8

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Method

Results

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

Transparent criteria for specialist level adolescent psychiatric care

Remitting brief psychotic disorder in a 15-year-old male

Consequences of prenatal toxin exposure for mental health in children and adolescents

Exposure to HIV in Brazilian adolescents: the impact of psychiatric symptomatology

Temperament, life events, and psychopathology among the offspring of bipolar parents